Author:
Liu Yang,Liang Jing,Zhu Rui,Yang Yueying,Wang Yali,Wei Wenyi,Li Hua,Chen Lixia
Abstract
Proteolysis targeting chimeras (PROTACs), as a novel therapeutic drug model, has received widespread attention from academia and the pharmaceutical industry. PROTAC technology has led researchers to focus on developing chemical biology tool properties due to the unique operating mechanism and protein dynamic regulatory properties. In recent years the rapid development of PROTAC technology has gradually made PROTACs an essential tool for target identification and validation. To further promote the application of PROTAC tools in drug discovery and basic medical science research, this review distinguished target identification and validation concepts. Furthermore, research progress in PROTAC technology was summarized.
Reference114 articles.
1. Protacs: Chimeric Molecules that Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation;KM Sakamoto;Proceedings of the National Academy of Sciences of the United States of America,2001
2. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP;M Zheng;Journal of Medicinal Chemistry,2021
3. PROTAC-DB: http://cadd.zju.edu.cn/protacdb/browse/compound
4. Protein Degraders Enter the Clinic - A New Approach to Cancer Therapy;D Chirnomas;Nature Reviews. Clinical Oncology,2023
5. KYMERA: Reinventing Medicine with Protein Degradation;Kymera